Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineReferences
- Increasing prevalence of atrial fibrillation and flutter in the United States.Am J Cardiol. 2009; 104: 1534-1539
- Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US.Blood. 2005; 106: 910
- A pharmacologic overview of current and emerging anticoagulants.Cleve Clin J Med. 2005; 72: S2-S6
- Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361: 1139-1151
- Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.N Engl J Med. 2012; 366: 1287-1297
- Dabigatran versus warfarin in the treatment of acute venous thromboembolism.N Engl J Med. 2009; 361: 2342-2352
- Dabigatran and postmarketing reports of bleeding.N Engl J Med. 2013; 368: 1272-1274
U.S. Food and Drug Administration. Pradaxa (dabigatran etexilate meslate): drug safety communication - safety review of post-market reports of serious bleeding events. 2012. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm282820.htm. Accessed August 6, 2013.
- Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.Ann Emerg Med. 2013; 61: 475-479
- Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?.Thromb Haemost. 2014; 111: 189-198
- Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004; 126: 287S-310S
- Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.Circulation. 2006; 114: 774-782
IMS. IMS data US National Prescription Audit; MAT (moving annual total) 2011–2012.
- Medication use leading to emergency department visits for adverse drug events in older adults.Ann Intern Med. 2007; 147: 755-765
- Emergency hospitalizations for adverse drug events in older Americans.N Engl J Med. 2011; 365: 2002-2012
- Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.Arch Intern Med. 2007; 167: 1414-1419
- Effect of anticoagulant and antiplatelet therapy in patients with spontaneous intra-cerebral hemorrhage: does medication use predict worse outcome?.Clin Neurol Neurosurg. 2010; 112: 275-281
- Warfarin use leads to larger intracerebral hematomas.Neurology. 2008; 71: 1084-1089
- Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality.Stroke. 1993; 24: 987-993
- Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study.Stroke. 2011; 42: 2431-2435
- The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.Arch Intern Med. 2004; 164: 880-884
- The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation.Thromb Haemost. 2013; 109: 431-439
- Rates of hemorrhage during warfarin therapy for atrial fibrillation.CMAJ. 2013; 185: E121-E127
- Novel oral anticoagulants in gastroenterology practice.Gastrointest Endosc. 2013; 78: 227-239
- Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients.Int J Cardiol. 2013; 167: 1237-1241
- Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.Am J Cardiol. 2012; 110: 453-460
- Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.Heart. 2013; 100: 324-335
Australian Therapeutic Goods Administration (TGA). Dabigatran (Pradaxa) and risk of bleeding: information for health professionals. 2013. Available at: http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm. Accessed September 3, 2013.
European Medicines Agency (EMA). European Medicines Agency updates patient and prescriber information for Pradaxa. 2012. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/05/news_detail_001518.jsp&mid=WC0b01ac058004d5c1. Accessed September 4, 2013.
Boehringer Ingelheim. Boehringer Ingelheim announces agreement to study real-world use of oral anticoagulants. 2013. Available at: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/08-15-13-boehringer-ingelheim-announces-agreement-study-real-world-use-oral-anticoagulants.html. Accessed September 9, 2013.
- Cross-sectional guidelines for therapy with blood components and blood derivatives; plasma for therapeutic use.Transfus Med Hemother. 2009; 26: 388-397
- Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012; 141: e152S-e184S
- Guidelines on oral anticoagulation with warfarin - fourth edition.Br J Haematol. 2011; 154: 311-324
- French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding).Thromb Res. 2010; 126: e167-e174
- Management of bleeding and coagulopathy following major trauma: an updated European guideline.Crit Care. 2013; 17: R76
- Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.Circulation. 2013; 128: 1234-1243
- European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.Europace. 2013; 15: 625-651
- Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.Thromb Haemost. 2012; 107: 838-847
- Managing new oral anticoagulants in the perioperative and intensive care unit setting.Anesthesiology. 2013; 118: 1466-1474
- Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).Thromb Haemost. 2011; 106: 868-876
- Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor.Thromb Haemost. 2012; 108: 876-886
- Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.Arch Cardiovasc Dis. 2013; 106: 382-393
- Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012; 141: e44S-e88S
- Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.Am J Hematol. 2012; 87: S141-S145
- Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.Cleve Clin J Med. 2013; 80: 443-451
Queensland Health. Guideline for managing patients on dabigatran (Pradaxa®). 2013. Available at: http://www.health.qld.gov.au/qhcss/mapsu/documents/dabigatran_info.pdf. Accessed September 9, 2013.
- Emergency management of bleeding associated with old and new oral anticoagulants.Clin Cardiol. 2012; 35: 730-737
- Managing bleeding in anticoagulated patients in the emergency care setting.J Emerg Med. 2013; 45: 467-477
- New direct oral anticoagulants – current therapeutic options and treatment recommendations for bleeding complications.Thromb Haemost. 2012; 108: 625-632
- Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers.Thromb Haemost. 2012; 108: 217-224
- Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.Thromb Haemost. 2013; 110: 162-172
- Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.Stroke. 2013; 44: 771-778
- Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.Circulation. 2011; 124: 1573-1579
- Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban (2013 ISTH abstracts).J Thromb Haemost. 2013; 11: 167
- Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.Thromb Res. 2013; 132: e161-e163
- Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.Crit Care Med. 2013; 41: e42-e46
- Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.Haematologica. 2013; 98: e143-e144
- Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.Am J Health Syst Pharm. 2012; 69: 1646-1650
- Treatment of dabigatran-associated bleeding: case report and review of the literature.J Pharm Pract. 2013; 26: 264-269
- Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.Thromb Haemost. 2013; 109: 596-605
- Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.Am J Geriatr Pharmacother. 2012; 10: 160-163
- Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.Blood. 2012; 119: 2172-2174
- An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models.J Thromb Haemost. 2011; 9: 1-970
- A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.Nat Med. 2013; 19: 446-451
- The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.Haematologica. 2007; 92: 199-205
Bayer Pharma AG. Xarelto® – Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed September 10, 2013.
Boehringer Ingelheim. Pradaxa® – Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/05/WC500127777.pdf. Accessed September 10, 2013.
Bristol-Myers Squibb. Eliquis® – Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed September 10, 2013.
- How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.Blood. 2012; 119: 3016-3023
Article info
Publication history
Footnotes
Conflict of Interest Statements: Prof. J.H. Levy serves on steering committees for Boehringer Ingelheim, CSL Behring AG, Grifols, Janssen Pharmaceuticals, and The Medicines Company. Prof. M. Levi has received research grants from Sanquin and CSL Behring, and has been on advisory boards of Bayer, LFB, and Johnson & Johnson.
Editorial assistance was provided by Chrystelle Rasamison at Fishawack Communications Ltd, UK, with a grant from CSL Behring, Marburg, Germany.
